BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32506337)

  • 1. Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study.
    Plym A; Johansson ALV; Bower H; Wennstig AK; Fredriksson I; Ahlgren J; Lambe M
    Breast Cancer Res Treat; 2020 Aug; 182(3):699-707. PubMed ID: 32506337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causes of sick leave, disability pension, and death following a breast cancer diagnosis in women of working age.
    Plym A; Johansson ALV; Bower H; Voss M; Holmberg L; Fredriksson I; Lambe M
    Breast; 2019 Jun; 45():48-55. PubMed ID: 30852409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study.
    Plym A; Clements M; Voss M; Holmberg L; Stattin P; Lambe M
    BMJ Open; 2020 Mar; 10(3):e032914. PubMed ID: 32156761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sickness absence and disability pension following breast cancer - A population-based matched cohort study.
    Lundh MH; Lampic C; Nordin K; Ahlgren J; Bergkvist L; Lambe M; Berglund A; Johansson B
    Breast; 2014 Dec; 23(6):844-51. PubMed ID: 25305791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
    Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Breast Reconstruction on Time to Definitive Surgical Treatment, Adjuvant Therapy, and Breast Cancer Outcomes.
    Jabo B; Lin AC; Aljehani MA; Ji L; Morgan JW; Selleck MJ; Kim HY; Lum SS
    Ann Surg Oncol; 2018 Oct; 25(10):3096-3105. PubMed ID: 30014454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
    Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
    Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤35 years) and young (36-45 years) breast cancer patients.
    Szollár A; Újhelyi M; Polgár C; Oláh E; Pukancsik D; Rubovszky G; Udvarhelyi N; Kovács T; Sávolt Á; Kenessey I; Mátrai Z
    Eur J Surg Oncol; 2019 Nov; 45(11):2009-2015. PubMed ID: 31189512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
    Park S; Lee SK; Paik HJ; Ryu JM; Kim I; Bae SY; Yu J; Kim SW; Lee JE; Nam SJ
    Medicine (Baltimore); 2017 Jun; 96(22):e6777. PubMed ID: 28562530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment.
    Nord C; Olofsson SE; Glimelius I; Cedermark GC; Ekberg S; Cavallin-Ståhl E; Neovius M; Jerkeman M; Smedby KE
    Acta Oncol; 2015 Nov; 54(10):1770-80. PubMed ID: 25833328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arm morbidity and sick leave among working women shortly after breast cancer surgery.
    Wennman-Larsen A; Olsson M; Alexanderson K; Nilsson MI; Petersson LM
    Eur J Oncol Nurs; 2013 Feb; 17(1):101-6. PubMed ID: 22705269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
    Panoff JE; Hurley J; Takita C; Reis IM; Zhao W; Sujoy V; Gomez CR; Jorda M; Koniaris L; Wright JL
    Breast Cancer Res Treat; 2011 Aug; 128(3):899-906. PubMed ID: 21475999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
    Gonçalves A; Pierga JY; Ferrero JM; Mouret-Reynier MA; Bachelot T; Delva R; Fabbro M; Lerebours F; Lotz JP; Linassier C; Dohollou N; Eymard JC; Leduc B; Lemonnier J; Martin AL; Boher JM; Viens P; Roché H
    Ann Oncol; 2015 Aug; 26(8):1692-7. PubMed ID: 25943350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.